• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ablynx, Merck extend ion channel research collaboration

Ablynx, Merck extend ion channel research collaboration

March 27, 2015
CenterWatch Staff

Ablynx, a biopharmaceutical company headquartered in Belgium, has extended its initial two-year research collaboration with Merck to develop and commercialize Nanobody candidates directed toward an undisclosed voltage gated ion channel.

Merck will extend its funding of the research collaboration with Ablynx to the end of September 2016. This ion channel collaboration was announced in October 2012 and included a $7.1 million upfront payment and $2.2 million in initial research funding.

Merck and Ablynx have a separate collaboration in the field of cancer immuno-therapy, announced in February in 2014, with a $21.8 million upfront payment, $11.6 million in research funding and total potential milestone payments of up to $1.8 billion plus royalties.

Dr. Edwin Moses, CEO of Ablynx, said, "We are pleased to extend the research funding for our current ion channel collaboration with Merck. To date, we have made encouraging progress in the discovery of Nanobodies against this very challenging target and the extension will potentially allow us to build on these advances." 

As part of its hybrid model of developing its wholly-owned assets and partnering some programs, Ablynx has R&D collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck, Merck Serono and Novartis involving more than 20 active therapeutic programs and which already have generated more than $370 million in non-dilutive cash for the company.

In October 2012, Ablynx and a subsidiary of Merck entered into a collaboration to develop and commercialize Nanobody candidates directed towards a voltage gated ion channel, with the option to develop and commercialize a Nanobody to a second target. Merck gains exclusive global rights to Nanobodies against the selected target, with an option for similar rights to a second target.

Merck paid Ablynx a $7.1 million upfront payment. In addition, Ablynx is eligible to receive research funding and up to $486.8 million in research, regulatory and commercial milestone payments associated with the progress of multiple candidates, as well as tiered royalties on any products derived from the collaboration. Ablynx is responsible for the discovery of Nanobody candidates and Merck is responsible for the research, development, manufacturing and commercialization of any Nanobody product resulting from the collaboration.

Upcoming Events

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing